Terms: = Uterine cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
199 results:
1. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
[TBL] [Abstract] [Full Text] [Related]
2. Ultrasound-Triggered Azo Free Radicals for Cervical cancer Immunotherapy.
Wang Y; Lv B; Wang H; Ren T; Jiang Q; Qu X; Ni D; Qiu J; Hua K
ACS Nano; 2024 Apr; 18(17):11042-11057. PubMed ID: 38627898
[TBL] [Abstract] [Full Text] [Related]
3. Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis.
Liang KW; Chen LJ; Wang CH; Ma KS; Hsia LH; Wang PH
Front Immunol; 2024; 15():1331994. PubMed ID: 38562939
[TBL] [Abstract] [Full Text] [Related]
4. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
5. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
Peters I; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2024 Mar; 34(3):352-362. PubMed ID: 38438181
[TBL] [Abstract] [Full Text] [Related]
6. Incorporation of anti-pd1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
[TBL] [Abstract] [Full Text] [Related]
7. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line treatment in Recurrent or Metastatic Cervical cancer (COMPASSION-13): A Phase 2 Study.
Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
[TBL] [Abstract] [Full Text] [Related]
8. Clinical benefit analysis of pd-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
[TBL] [Abstract] [Full Text] [Related]
9. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
10. Prevalence of PD-L1 in Cervical cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract] [Full Text] [Related]
11. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
[TBL] [Abstract] [Full Text] [Related]
12. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
13. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract] [Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract] [Full Text] [Related]
15. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical cancer.
Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
[TBL] [Abstract] [Full Text] [Related]
16. PD-L1 and pd-1 Expression in Early Stage uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
17. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
[TBL] [Abstract] [Full Text] [Related]
18. pd-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
de Moraes FCA; Pasqualotto E; Lopes LM; Cavalcanti Souza ME; de Oliveira Rodrigues ALS; de Almeida AM; Stecca C; Fernandes MR; Dos Santos NPC
BMC Cancer; 2023 Nov; 23(1):1166. PubMed ID: 38031003
[TBL] [Abstract] [Full Text] [Related]
19. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
20. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.
Zong Y; Chang Y; Huang K; Liu J; Zhao Y
Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570
[TBL] [Abstract] [Full Text] [Related]
[Next]